Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen
- PMID: 200161
- DOI: 10.7326/0003-4819-87-5-517
Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen
Abstract
Exogenous estrogens (ethinyl estradiol, 1 microgram/kg body weight per day), which stimulate triglyceride production in normal women and those with endogenous hypertriglyceridemia, were found to exert a paradoxical, hypolipidemic effect in six subjects (five women, one man) with type III hyperlipoproteinemia on diets both of normal and of fat-free, high-carbohydrate composition. Moreover, very low-density (VLD) lipoprotein lipid and apolipoprotein composition and electrophoretic mobility became normal during estrogen administration in these subjects. Levels of normal VLD lipoproteins remained mildly to moderately elevated in a type IV lipoprotein pattern. Estrogen withdrawal promptly restored the type III pattern with its abnormal enrichment of VLD lipoproteins with apolipoprotein E (the arginine-rich peptide). These findings suggest that estrogens facilitate the assimilation of chylomicron and VLD lipoprotein remnants, a defect that appears likely to represent the metabolic abnormality underlying type III hyperlipoproteinemia.
Similar articles
-
The spectrum of electrophoretic mobility of very low density lipoproteins: role of slower migrating species in endogenous hypertriglyceridemia (type IV hyperlipoproteinemia) and broad-beta disease (type III).J Lab Clin Med. 1975 Aug;86(2):239-52. J Lab Clin Med. 1975. PMID: 168277
-
A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.Horm Metab Res. 1986 Sep;18(9):607-10. doi: 10.1055/s-2007-1012386. Horm Metab Res. 1986. PMID: 3465673
-
Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia).Metabolism. 1976 Jul;25(7):777-801. doi: 10.1016/0026-0495(76)90149-9. Metabolism. 1976. PMID: 181657 Clinical Trial.
-
The common hyperlipoproteinemias: an understanding of disease mechanisms and their control.Ann Intern Med. 1976 Oct;85(4):497-508. doi: 10.7326/0003-4819-85-4-497. Ann Intern Med. 1976. PMID: 184730 Review.
-
[Familial hyperlipoproteinemia type III].Dtsch Med Wochenschr. 1976 Oct 29;101(44):1612-9. doi: 10.1055/s-0028-1104313. Dtsch Med Wochenschr. 1976. PMID: 185039 Review. German. No abstract available.
Cited by
-
Familial apolipoprotein E deficiency.J Clin Invest. 1986 Nov;78(5):1206-19. doi: 10.1172/JCI112704. J Clin Invest. 1986. PMID: 3771793 Free PMC article.
-
[The apolipoproteins in man ].Klin Wochenschr. 1982 Jul 1;60(13):673-49. doi: 10.1007/BF01716796. Klin Wochenschr. 1982. PMID: 6750220 Review. German.
-
Current concepts of the molecular structure and metabolism of human apolipoproteins and lipoproteins.Klin Wochenschr. 1981 Sep 15;59(18):1023-35. doi: 10.1007/BF01747745. Klin Wochenschr. 1981. PMID: 7029129 Review.
-
Sex steroid modulation of fatty acid utilization and fatty acid binding protein concentration in rat liver.J Clin Invest. 1980 May;65(5):1013-23. doi: 10.1172/JCI109753. J Clin Invest. 1980. PMID: 7364935 Free PMC article.
-
Very low density lipoprotein apolipoprotein B metabolism in humans.Klin Wochenschr. 1988 Aug 15;66(16):703-12. doi: 10.1007/BF01726412. Klin Wochenschr. 1988. PMID: 3050267 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources